The team evaluated the efficiency by which the 5-HT4 agonist cisapride affects important motor functions involved in the control of gastroesophageal reflux.
The results of the study were published in the January 2002 issue of the European Journal of Gastroenterology and Hepatology.
Some 30 patients with proven gastroesophageal reflux disease (endoscopy and 24 h pH-metry) were included in the randomized, double-blind study.
Cisapride, 20 mg twice daily, over 4 weeks was compared with placebo.
All patients underwent symptom assessments, sleeve manometry with concomitant esophageal pH monitoring, and an acid clearance test, at baseline, as well as after 4 and 8 weeks.
| Cisapride had no effect on motor mechanisms involved in GERD.
| European Journal of Gastroenterology & Hepatology |
Despite adequate plasma levels, cisapride had no significant effect on swallow-induced peristaltic amplitude, duration, propagation speed, the elicitation of secondary peristalsis, or on acid clearance.
It was found that neither the basal tone of the lower esophageal sphincter, nor the number of transient lower esophageal sphincter relaxations induced by gas distension of the stomach, was affected by the administered dose of cisapride.
Caterina Finizia, of the Sahlgrenska University Hospital, Gothenburg, concluded on behalf of her colleagues, "Cisapride has been alleged to improve symptoms as well as the esophagitis in patients with gastroesophageal reflux disease.
"However, we found the compound devoid of effects on important motor mechanisms involved in the pathogenesis of the disease."